Epratuzumab and Rituximab Have Strong Showing Against Follicular Lymphoma

Biopharmaceutical company Immunomedics announced that the combination of epratuzumab and rituximab as a front-line therapy for patients with newly diagnosed follicular non-Hodgkin's lymphoma (FL) resulted in a very high complete response rate among the small cohort as well as prolonged time to disease progression.

The company had the combination in the Phase II CALGB 50701 study, sponsored by the National Cancer Institute Study Group, Cancer and Leukemia Group B (CALGB). The findings appear online in the journal Cancer.

The overall response rate (ORR) among 59 evaluable patients was 88.2 percent.

Of these:
- 25 patients (42.4 percent) achieved a complete response
- 27 patients (45.8 percent) reported a partial response
- 6 patients (10.2 percent) had stable disease as their best response.

The estimated median progression-free survival is 3.5 years.

At 3 years, 60 percent of patients remain in remission.

Said Cynthia L. Sullivan, President and Chief Executive Officer of Immunomedics:

We are very encouraged with these high efficacy results of epratuzumab when combined with rituximab in patients with NHL who are naive to therapy. Further development of this humanized anti-CD22 antibody will be an international Phase III study conducted by the Resistant Disease Committee of the International BFM Study Group to improve the outcome of children and adolescents with acute lymphoblastic leukemia.

Epratuzumab is Immunomedics' proprietary humanized anti-CD22 antibody. It has shown efficacy as a monotherapy in relapsed FL. Although rituximab combined with chemotherapy has improved the survival of previously untreated patients with FL, many patients are unable or unwilling to tolerate chemotherapy.

Therefore CALGB chose to evaluate the combination of epratuzumab and rituximab as front-line therapy.

Source: WSJ

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap